We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ORAL T-8 Oral Testosterone for Male Hormonal Contraception (Oral T8)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01167829
First Posted: July 22, 2010
Last Update Posted: September 6, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
John Amory, University of Washington
Results First Submitted: September 25, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Health Services Research
Condition: Healthy
Interventions: Drug: Oral Testosterone
Drug: Acyline

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited through news media (website)and college campus bulletin boards in Seattle, WA. between July-September 2010. All visits were at the University of Washington, Seattle, WA.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
14 subjects were screened and 2 did not meet inclusion criteria for untreated high blood pressure and peripheral arterial disease.

Reporting Groups
  Description
Acyline and 0ral Testosterone Acyline 300 mcg/kg subcutaneous + 300mg modified slow-release oral testosterone tid

Participant Flow:   Overall Study
    Acyline and 0ral Testosterone
STARTED   12 
COMPLETED   12 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Acyline and Oral Testosterone 300 mcg/kg acyline, and modified slow-release oral testosterone 300 mg

Baseline Measures
   Acyline and Oral Testosterone 
Overall Participants Analyzed 
[Units: Participants]
 12 
Age 
[Units: Years]
Median (Inter-Quartile Range)
 28.1 
 (19 to 51) 
Gender 
[Units: Participants]
 
Female   0 
Male   12 
Region of Enrollment 
[Units: Participants]
 
United States   12 
Body Mass Index (BMI) 
[Units: Kg/m^2]
Mean (Standard Deviation)
 24.2  (1.5) 
Body Weight 
[Units: Kg]
Mean (Standard Deviation)
 79.9  (7.5) 
Follicle-stimulating hormone (FSH) 
[Units: IU/L]
Mean (Standard Deviation)
 3.2  (1.5) 
Luteinizing hormone (LH) 
[Units: IU/L]
Mean (Standard Deviation)
 5.4  (4.4) 
Testosterone 
[Units: ng/dL]
Mean (Standard Deviation)
 510  (13) 
Prostate-specific antigen (PSA) 
[Units: ng/mL]
Mean (Standard Deviation)
 0.91  (0.56) 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maximum Testosterone Concentration   [ Time Frame: baseline & day 9 ]

2.  Primary:   Mean Testosterone Concentration   [ Time Frame: baseline & day 9 ]

3.  Secondary:   Maximum Dihydrotestosterone (DHT) Concentration   [ Time Frame: baseline & day 9 ]

4.  Secondary:   Mean Dihydrotestosterone (DHT) Concentration   [ Time Frame: baseline & day 9 ]

5.  Secondary:   Maximum Sex Hormone-Binding Globulin (SHGB)Concentration   [ Time Frame: baseline & day 9 ]

6.  Secondary:   Mean SHGB Concentration   [ Time Frame: baseline & day 9 ]

7.  Secondary:   Maximum Estradiol Concentration   [ Time Frame: baseline & day 9 ]

8.  Secondary:   Mean Estradiol Concentration   [ Time Frame: baseline & day 9 ]

9.  Secondary:   Free T Maximum Concentration   [ Time Frame: baseline & day 9 ]

10.  Secondary:   Free Testosterone Mean Concentration   [ Time Frame: baseline & day 9 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: John Amory, MD
Organization: University of Washington, Dept. of Medicine
phone: (206) 616-1727
e-mail: jamory@u.washington.edu


Publications:
1. Plymate SR "Male Hypogonadism" in Principles and Practice of Endocrinology and Metabolism (3rd. Ed). Ed. Kenneth Becker, pp:1125-1150


Responsible Party: John Amory, University of Washington
ClinicalTrials.gov Identifier: NCT01167829     History of Changes
Other Study ID Numbers: 38636-D
First Submitted: July 20, 2010
First Posted: July 22, 2010
Results First Submitted: September 25, 2012
Results First Posted: August 23, 2013
Last Update Posted: September 6, 2013